Bioeksen R&D Technologies is a biotechnology company established in 2014 with the support of KOSGEB R&D Innovation, focused on innovative molecular technologies, engaged in R&D, production and sales. Founders of Bioeksen are academicians who are members of the Microbial Ecology Group (MEG), a joint organization of Istanbul Technical and Bogazici Universities. Since our establishment, 32 different R&D projects have been completed, and as a result of these projects, 164 different molecular biotechnology products have been released in the areas of human health, animal health, and food safety.
Bioeksen's innovation focuses on molecular technologies enabling healthcare providers to rapidly identify specific infections and to make timely clinical management decisions (e.g. hospitalization, isolation and antimicrobial treatment or lack thereof). Bioeksen's innovation focuses on molecular technologies detecting the disease agents in their source to timely control the transmission to human. Bioeksen has been carrying out extensive research on infectious agent specific molecular therapeutics to combine the power of its molecular diagnostics technologies with the targeted treatment that has not any side effects on human.
Bioeksen has a production capacity of 2 million tests/day. 200 million Bioeksen’s tests have been used in 60 different countries so far. Bioeksen has two different production facilities located in Turkey and Germany. Bioeksen operates ISO 13485 and 9001 quality management systems. Bioeksen’s molecular diagnostics solutions are in the top 5% that have both FDA and WHO approval among the 480 companies producing molecular tests in the world.